Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases.

Mei-Mei ZhengYang-Si LiHai-Yan TuHao SunKai YinBen-Yuan JiangJin-Ji YangXu-Chao ZhangQing ZhouChong-Rui XuZhen WangHua-Jun ChenDe-Xiang ZhouYi-Long Wu

Published in: BMC medicine (2022)

Private resistant mechanisms in CSF might match osimertinib-resistant LM for targeted therapy. Besides, continuing osimertinib with intensification strategy might prolong survival, especially for those with CNS-only progression. Prospective exploration is needed.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
epidermal growth factor receptor
brain metastases
tyrosine kinase
cerebrospinal fluid
healthcare
health insurance
blood brain barrier
medical education
wild type